Chief Medical Officer · Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Dominic Smethurst

A named executive officer of Corbus Pharmaceuticals in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,800,142

FY2024: $2,892,972

Compensation figures as of the proxy filed April 2, 2026 (DEF 14A).

Dominic Smethurst compensation by year

Corbus Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Corbus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$408,914$519,313
Bonus$0$168,078
Stock awards$1,303,500$266,288
Option awards$1,165,650$812,866
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$14,908$33,597
Total$2,892,972$1,800,142

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Corbus Pharmaceuticals Holdings, Inc. DEF 14A filed April 2, 2026, accession 0001193125-26-140363, and prior-year filings. Open the filing on EDGAR.

$2.9M
$1.8M
FY24
FY25
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU37,500$305,250—
PSU27,200$221,408—
Option91,200—$9.79
Option27,084—$26.07

Per the Outstanding Equity Awards at Fiscal Year-End table in Corbus Pharmaceuticals Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Corbus Pharmaceuticals discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause—$0——
Change in control and involuntary termination—$526,658——

Per the Potential Payments Upon Termination or Change in Control table in Corbus Pharmaceuticals Holdings, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

Corbus Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Yuval CohenChief Executive Officer and Director$3,750,125
Dominic Smethurst · this pageChief Medical Officer$1,800,142
Sean MoranChief Financial Officer$1,789,423

The full Corbus Pharmaceuticals compensation record

free company brief

This page is one person within Corbus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Corbus Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Corbus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy